Amgen Loses Appeal Over Antibody Patent in Sanofi Fight (1)

Feb. 11, 2021, 4:43 PM

Amgen Inc. lost an appeals court bid to revive two patents for its Repatha cholesterol drug, a victory for Sanofi and Regeneron Pharmaceuticals Inc. in their long-running fight over rival medicine Praluent.

A trial court was correct to invalidate the patents, the U.S. Court of Appeals for the Federal Circuit ruled Thursday in a closely watched case over how or whether patents can be granted for a new group of antibodies.

The two Amgen patents, which were due to expire in August 2028, are related to antibodies called PCSK9 inhibitors, which help patients with ultra-high bad, or LDL, cholesterol who ...

To read the full article log in.

Learn more about a Bloomberg Law subscription